Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
04:01pm, Thursday, 06'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided bus
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
02:43pm, Tuesday, 14'th Oct 2025
The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.'s (NASDAQ:DNLI) review timeline of the Biologics License Application (BLA), seeking accelerated approval of tividenofu
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
09:26am, Tuesday, 14'th Oct 2025
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
04:01pm, Monday, 13'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
12:30pm, Wednesday, 10'th Sep 2025
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
02:31am, Tuesday, 09'th Sep 2025
Denali Therapeutics Inc. (NASDAQ:DNLI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Ryan Watts - Co-Founder, President, CEO & Director Co
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
09:21am, Tuesday, 12'th Aug 2025
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
04:01pm, Monday, 11'th Aug 2025
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval pat
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
11:01am, Tuesday, 08'th Jul 2025
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
12:37pm, Thursday, 05'th Jun 2025
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
02:10pm, Wednesday, 07'th May 2025
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA?
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
10:15am, Monday, 05'th May 2025
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
10:35am, Thursday, 03'rd Apr 2025
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
